pCDNA3-HA-human MYCN Citations (4)
Originally described in: The Interaction of Myc with Miz1 Defines Medulloblastoma Subgroup Identity.Vo BT, Wolf E, Kawauchi D, Gebhardt A, Rehg JE, Finkelstein D, Walz S, Murphy BL, Youn YH, Han YG, Eilers M, Roussel MF Cancer Cell. 2016 Jan 11;29(1):5-16. doi: 10.1016/j.ccell.2015.12.003. PubMed Journal
Articles Citing pCDNA3-HA-human MYCN
Articles |
---|
Interleukin-like EMT inducer (ILEI) promotes melanoma invasiveness and is transcriptionally up-regulated by upstream stimulatory factor-1 (USF-1). Noguchi K, Dincman TA, Dalton AC, Howley BV, McCall BJ, Mohanty BK, Howe PH. J Biol Chem. 2018 Jul 20;293(29):11401-11414. doi: 10.1074/jbc.RA118.003616. Epub 2018 Jun 5. PubMed |
Targeting the Difficult-to-Drug CD71 and MYCN with Gambogic Acid and Vorinostat in a Class of Neuroblastomas. Bishayee K, Habib K, Sadra A, Huh SO. Cell Physiol Biochem. 2019;53(1):258-280. doi: 10.33594/000000134. PubMed |
MicroRNA-493-5p-mediated repression of the MYCN oncogene inhibits hepatic cancer cell growth and invasion. Yasukawa K, Liew LC, Hagiwara K, Hironaka-Mitsuhashi A, Qin XY, Furutani Y, Tanaka Y, Nakagama H, Kojima S, Kato T, Ochiya T, Gailhouste L. Cancer Sci. 2020 Mar;111(3):869-880. doi: 10.1111/cas.14292. Epub 2020 Jan 25. PubMed |
PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. Boi D, Souvalidou F, Capelli D, Polverino F, Marini G, Montanari R, Pochetti G, Tramonti A, Contestabile R, Trisciuoglio D, Carpinelli P, Ascanelli C, Lindon C, De Leo A, Saviano M, Di Santo R, Costi R, Guarguaglini G, Paiardini A. Int J Mol Sci. 2021 Dec 4;22(23). pii: ijms222313122. doi: 10.3390/ijms222313122. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.